Dr Jonathan Nambiar joined channel bio in 2019 with over 10 years of industry experience. He was previously a manager at Bio-Link Australia, a firm assisting various biotechnology clients with business development and project management activities. Prior to Bio-Link, Jonathan worked in finance as an equities research analyst at Magellan, an Australian fund manager, providing investment recommendations on publicly-listed biopharmaceutical companies. Prior to Magellan, he completed postdoctoral work with Adam Clarke in antibody therapeutics R&D at Cephalon, later acquired by Teva Pharmaceuticals where he worked as a senior research scientist. Jonathan earned a PhD in infectious diseases and immunology from the University of Sydney (Prof. Jamie Triccas/Warwick Britton labs), and an MBA from the University of Newcastle.